Calendar
Top-down
A look at earnings from the view of macro-economists and market technicians
Market Overview
Heat Map
Sentiment
Technicals
Retail Sales
Pricing
Manu-facturing
Economic Cycle
Bottom-up
A bottom-up view of earnings from professional equity analysts
Earnings Highlights
Date Trades
Earnings News
Pivots
Earnings Cycle
Sector Analysis
Investor
Trader
Support
Documentation, research, and support for the information provided
Indicators
Results
About Us
Library
Contact Us
Plays
Score
Grade
Sign In
Sign In
or
Register
Forgot Password?
OR
Sign in using:
Don't have an account?
Register
VRTX
$237.64
Vertex Pharmaceutic
($3.67)
(1.52%)
VRTX
Earnings Whisper ®
$2.73
4th Quarter December 2020
Consensus: $2.59
Revenue: $1.57 Bil
Monday
Feb 1
4:00 PM ET
Score
Grade
Tweet
Share
Watch
Sentiment
Analysts
Sentiment
Analysts
Tweet
Share
Watch
Latest EPS
Thursday, October 29, 2020
Vertex Reports Third-Quarter 2020 Financial Results
What do you expect when VRTX reports earnings?
Beat
Meet
Miss
Where is VRTX's stock price going from here?
Up
Flat
Down
Analysts
Score
Grade
Sentiment
Analysts
Pivots
Resistance
$247.13
$245.06
$243.18
$241.12
Support
$239.24
$237.17
$235.30
Tweet
Trends
Short-term Price
Intermediate-term Price
Long-term Price
Investors' Sentiment
Analysts' Sentiment
Earnings Estimates
Growth
Description
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases.
Peers
InterCept
Regeneron Pharmaceuticals
BioMarin Pharmaceutical
Zoetis
Bristol-Myers Squibb
Pfizer
Merck & Co.
Eli Lilly
Johnson & Johnson
Catalent
Expectations
›
Vertex Pharmaceutic